MedTrace Logo

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

NCT06399757 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-01-07

No results posted yet for this study

Summary

This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).

Conditions

Interventions

DRUG

APL-5125

APL-5125 is an oral drug (capsule) taken daily in 28-day cycles

Sponsors & Collaborators

  • Apollo Therapeutics Ltd

    lead INDUSTRY

Principal Investigators

  • Sanjay Aggarwal, MD · Apollo Therapeutics Ltd

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-18
Primary Completion
2027-04-30
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06399757 on ClinicalTrials.gov